L'intérêt à découvert pour Sonnet BioTherapeutics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Sonnet BioTherapeutics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Sonnet BioTherapeutics (NASDAQ:SONN) Stock, Rapport sur les intérêts à découvert

Sonnet BioTherapeutics

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

One investor recently turned to Reddit&#8217;s <a href="https://www.reddit.com/r/stocks/comments/1lkq7v7/what_percentage_of_cash_are_you_holding_now/">r/stocks</a> community with a simple but revealing question: &#8220;What percentage of cash are you holding now?&#8221; With markets pushing new highs and macro risks looming, he explained he was sitting on 25% cash, citing high price-to-earnings ratios, global tensions and general unease as his reasons for holding back.
<h2 class="wp-block-heading">A Divided Crowd: From All-In To All-Out</h2>
The thread drew comments from people across the investing spectrum. Some were fully invested, others had pulled out almost entirely. The most commonly cited ranges were between 0% and 5% for long-term investors, and up to 50% or more for those bracing for a downturn.
&#8220;<a href="https://www.benzinga.com/personal-finance/management/25/06/45848783/need-quick-cash-christine-benzs-top-5-tips-to-boost-your-emergency-fund">Emergency fund</a> only,&#8221; one top commenter said. &#8220;There are always risks and you miss out on a lot of potential by sitting on the sidelines. Most people <a href="https://www.benzinga.com/markets/equities/25/04/44610661/why-timing-the-market-is-a-terrible-idea">fail in trying to time the market</a> like this.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a></li>
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. </a></li>
</ul>
Another added, &#8220;I'm about 80% cash&#8230; I know I'm an idiot statistically speaking. Timing the market is bad. I get it. But damn it. I watch our government behave like children and freak the f out.&#8221;
Some users held cash strictly because of interest rates. &#8220;Cash is paying 4.2%, and many mortgages are locked in at less than that,&#8221; one person noted. &#8220;The opportunity cost of avoiding what appears to be a teetering market is pretty low.&#8221;
Others stayed aggressive. &#8220;I don't keep cash lying around, that's a waste of resources. You need to be in the market,&#8221; a user said.
Still, many agreed that the market feels unusual right now. One wrote, &#8220;If things aren't <a href="https://www.benzinga.com/money/is-it-a-good-time-to-invest-in-the-stock-market">objectively risky</a> right now, then when? Risk should have tanked this market twice over, but everything gets shrugged off.&#8221;
Trending: GoSun's Breakthrough Rooftop EV Charger Already Has 2,000+ Units Reserved — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Become an Investor in This $41.3M Clean Energy Brand Today</a>&nbsp;
Some admitted to recent panic selling, missing rallies, or simply feeling confused. &#8220;I pulled out in February/March before <a href="https://www.benzinga.com/markets/25/05/45486508/scott-bessent-signals-liberation-day-2-0-coming-if-countries-dont-sign-trade-deals-president-trump-has-put-them-on-notice">Liberation day</a>, convinced the sky was falling&#8230; then got back in once most of it recovered,&#8221; a commenter said. &#8220;I'm sure all I've done is incur tax events, but I know I'm not unique in this monkey behavior.&#8221;
Several mentioned they were holding 10% to 30% cash as a buffer or &#8220;dry powder.&#8221;&nbsp;
A number of investors pointed out that <a href="https://www.benzinga.com/markets/24/08/40431340/berkshires-latest-move-outpacing-the-fed-with-short-term-u-s-treasury-bills-what-buffett-knows-that">short-term Treasuries</a>, <a href="https://www.benzinga.com/money/best-high-yield-savings-accounts">high-yield savings accounts</a>, and <a href="https://www.benzinga.com/markets/bonds/25/06/46087443/money-market-funds-on-fire-as-902-billion-pours-in-why-these-safe-haven-investments-are-thriving-now">money market funds</a> were offering 4% to 5%, giving them less urgency to jump back into equities. &#8220;Why not get 4.5% on your emergency fund that's sitting around doing nothing in a savings account earning .01%?&#8221; a person asked.
Not everyone was anxious, though. &#8220;Zero. It's bull market time,&#8221; one said. Another added, &#8220;0% cash. I have no clue what's going to happen&#8230; I&#8217;ll keep putting money in every paycheck.&#8221;
One of the more reflective voices concluded, &#8220;Don't underestimate how much crazy sh&#x2A;t and risk is already priced in. A lot of people, myself included, would rather hold and have the market dip than sell and watch it pump.&#8221;
Read Next:
<ul class="wp-block-list">
<li>Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
Image: Shutterstock

News

An Investor Asks Others, 'What Percentage Of Cash Are You Holding Now?' High P/E Ratios And Geopolitical Risk Have Him Holding Back

Senator Cynthia Lummis (R-WY) has introduced a sweeping digital asset tax reform bill aimed at modernizing how cryptocurrencies are taxed in the United States, renewing her efforts to ease <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46227149/every-new-trillion-of-debt-in-trumps-big-beautiful-bill-is-free-adertising-for-bitcoin-expert-states">regulatory burdens on digital asset users.</a>
What Happened: The legislation, <a href="https://www.lummis.senate.gov/press-releases/lummis-unveils-digital-asset-tax-legislation/">unveiled</a> on July 3, proposes to resolve several long-standing tax complications in the crypto sector, including a $300 de minimis exemption for small transactions, more practical tax treatment for mining and staking, and bringing parity between digital assets and traditional financial instruments.
"In order to maintain our competitive edge, we must change our tax code to embrace our digital economy, not burden digital asset users," Lummis said in a statement. 
She described the bill as fully paid for, designed to cut through red tape, and aimed at aligning tax rules with how digital technologies work in practice.
The bill addresses multiple areas that have been problematic for crypto users:
<ul class="wp-block-list">
<li>A de minimis rule would exempt gains from small transactions, up to $300 per transaction and capped at $5,000 annually, easing tax tracking for everyday crypto use such as small purchases.</li>
<li>Digital asset lending agreements would no longer be treated as taxable events, aligning crypto lending with the well-established securities lending framework.</li>
<li>A wash sale rule would now apply to digital assets, closing a tax loophole that allowed crypto traders to harvest tax losses in ways not permitted for stock investors.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46248538/bitcoin-ethereum-solana-treasury-companies-need-to-manage-market-volatility-franklin-templeton-report-warns">Bitcoin, Ethereum, Solana Treasury Companies Need To Manage Market Volatility, Franklin Templeton Report Warns</a>
<ul class="wp-block-list">
<li>The bill also introduces a mark-to-market tax election for digital asset dealers and traders, providing consistent treatment with their securities and commodities counterparts.</li>
<li>For miners and stakers, income recognition would be deferred until assets are sold, addressing liquidity concerns for those taxed on unrealized gains.</li>
<li>Additionally, the bill would remove the appraisal requirement for charitable donations of actively traded digital assets, encouraging more philanthropy from crypto holders.</li>
</ul>
The Congressional Joint Committee on Taxation estimates the proposed reforms would generate about $600 million in net revenue over the 2025-2034 period.
What&#8217;s Next: Lummis invited public feedback on the bill, signaling her intention to build bipartisan support as she works to advance the legislation through Congress.
The Wyoming Republican's new crypto tax proposal closely mirrors the measures she previously attempted to include in a broader legislative package introduced earlier this week.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46244196/bitcoin-ethereum-poised-for-bullish-july-experts-say-but-only-one-is-underowned">Bitcoin, Ethereum Poised For Bullish July, Experts Say, But Only One Is &#8216;Underowned&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Crypto Tax Loopholes Closing? A Look Inside 'Bitcoin Senator' Lummis' New Bill

Morgan Stanley analyst Manan Gosalia upgrades Valley Ntl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLY#NASDAQ">VLY</a>) from Equal-Weight to Overweight and raises the price target from $10 to $11.

Upgrades

Price Target

Analyst Ratings

Morgan Stanley Upgrades Valley Ntl to Overweight, Raises Price Target to $11

U.S. stocks surged to new record highs on Thursday, with Wall Street celebrating stronger-than-expected labor market data ahead <a href="https://www.benzinga.com/markets/economic-data/25/07/46244105/june-jobs-report-nonfarm-payroll-adp-data">of the July 4 holiday.</a>
The S&amp;P 500 was eyeing 6,300, while the Nasdaq 100 climbed to 22,860. The Dow Jones Industrial Average also rallied, coming close to 44,900 — just shy of its January peak. Small caps joined the rally, with the Russell 2000 up nearly 1%.
Investor sentiment was boosted by June's nonfarm payrolls report, which showed the U.S. economy added 147,000 jobs — well above the 110,000 forecast. The data helped ease concerns stoked by a weak private payroll report just a day earlier.
Tech stocks led the charge, with the so-called Magnificent Seven reaching a combined market cap of $18.1 trillion. NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) solidified its lead as the world's most valuable company, surpassing a $3.9 trillion valuation, ahead of Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>) at $3.7 trillion.
Gains were broad-based across sectors, with only consumer staples slipping 0.1%. Technology and financials outperformed.
In bond markets, Treasury yields rose for a second straight session. The 30-year yield hit 4.85% as the U.S. Senate-passed "One Big Beautiful Bill" advanced to the House.
The upbeat jobs report also lifted the U.S. dollar. The DXY index gained 0.4%, with traders scaling back expectations for a rate cut in July — now pricing in just a 7% chance, down from 25% the day before.
Commodities came under pressure as the dollar strengthened. Gold fell 0.5%, oil slipped 1% and copper declined 1.1%.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) held steady near $109,700.
<h1 class="wp-block-heading">Thursday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day chg. %</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>22,867.69</td>
<td>1.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,281.57</td>
<td>0.9%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,864.37</td>
<td>0.9%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,244.57</td>
<td>0.8%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:50 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) rose 0.9% to $575.03.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.9% to $448.52.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rallied 1% to $555.99.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.9% to $222.99.</li>
<li>The&nbsp;Technology&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 1.5%; the&nbsp;Consumer Staples&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) lagged, down 0.1%.</li>
</ul>
<h1 class="wp-block-heading">Thursday&#8217;s Stock Movers</h1>
<ul class="wp-block-list">
<li>Datadog Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) stock was up 14.92% at $155.15 after news of its upcoming addition to the S&amp;P 500 and a Wedbush price target hike from $140 to $170.</li>
<li>Lennar Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) fell 4.09% to $110.12 as stronger-than-expected jobs data dampened hopes for Fed rate cuts.</li>
</ul>
Read Now:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46225431/alphabet-stock-google-analysis-valuations-outlook">This Magnificent 7 Stock Is Absurdly Cheap – It Probably Won&#8217;t Stay That Way For Long</a> Photo: Shutterstock<a href="https://www.benzinga.com/markets/tech/25/07/46225431/alphabet-stock-google-analysis-valuations-outlook"> </a></li>
</ul>

Equities

Macro Economic Events

Broad U.S. Equity ETFs

Commodities

Economics

Tech

ETFs

$BTC

DDOG

SPDR Dow Jones Industrial Average ETF Trust

MSFT

NVDA

Wall Street Soars To New Highs, Magnificent 7 Top $18 Trillion: What's Moving Markets Thursday?

Morgan Stanley analyst Maxwell Skor assumes Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Overweight rating and announces Price Target of $250.

Initiation

ASND

Morgan Stanley Assumes Ascendis Pharma at Overweight, Announces Price Target of $250

While Jim Cramer is staying far away, some contrarian investors are leaning in. Nebius Group NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIS#NASDAQ">NBIS</a>), a lesser-known <a href="https://www.benzinga.com/topic/artificial-intelligence">AI infrastructure startup</a> with Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) backing and Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)-level ambition, is quietly building one of the most intriguing bets in autonomous mobility and decentralized AI. 
And that makes it the perfect "Inverse Cramer" play.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/46165787/cramer-praises-monster-beverage-as-smoking-hot-warns-investors-about-this-ai-stock">Cramer Praises Monster Beverage As &#8216;Smoking Hot,&#8217; Warns Investors About This AI Stock</a>
<h2 class="wp-block-heading">Uber's Autonomous Sidekick: Nebius&#8217; Avride</h2>
At the heart of Nebius is its U.S.-based subsidiary, Avride Inc., which began life in 2020 as a spin-off from Yandex's self-driving car unit. Today, Avride is powering real-world robotaxis and delivery bots for Uber Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) and Uber Eats &#8211; with operations already live in Austin, Dallas, and Jersey City.
Think of it as Tesla's software brain meets Nvidia's compute muscle, but focused on the "infrastructure stack" of autonomous mobility. Avride's self-driving vehicles—retrofitted Hyundai Ioniq 5s—are packed with lidars, radars, and custom compute hardware. The company is also deploying sidewalk-speed delivery robots that cross streets, navigate traffic lights, and are already in action from the U.S. to Seoul.
<h2 class="wp-block-heading">The Hyundai Catalyst</h2>
In March 2025, Nebius struck a strategic partnership with Hyundai to develop commercial robotaxis, adding another heavyweight to its corner. Meanwhile, all manufacturing of its delivery robots is happening in Taiwan—giving it supply chain muscle to match its technical stack.
But Nebius isn't just about the vehicles—it's about controlling the AI infrastructure behind them. With Nvidia's blessing and without the baggage of legacy automakers, Nebius is aiming to become the sovereign AI operating system for autonomous mobility, one city and one robot at a time.
And then there&#8217;s the kicker: Jim Cramer <a href="https://www.youtube.com/watch?v=8CqSagdY6QI">isn't buying</a> in. The CNBC host recently passed on the stock, which for <a href="https://x.com/DailyInvestin/status/1940430021434433819">some</a> investors is a bullish signal in itself. In a market chasing hype, Nebius is building. Quietly. Globally. Relentlessly.
If you&#8217;re hunting for the next Tesla-style moonshot with Nvidia pedigree &#8211; and like a little Cramer-contrarianism on the side &#8211; Nebius might just be your AI dark horse.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45951960/golden-cross-alert-nvidia-backed-ai-stock-just-broke-out-is-this-the-next-big-winner">Golden Cross Alert: Nvidia-Backed AI Stock Just Broke Out &#8211; Is This The Next Big Winner?</a></li>
</ul>
Image: Shutterstock

Long Ideas

Trading Ideas

NBIS

TSLA

UBER

The Inverse Cramer AI Play: How Nebius Combines Tesla Vibes With Nvidia Muscle

Morgan Stanley analyst Maxwell Skor assumes Sana Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) with a Overweight rating and announces Price Target of $12.

SANA

Morgan Stanley Assumes Sana Biotechnology at Overweight, Announces Price Target of $12

Wall Street is basking in record highs as the S&amp;P 500 breaks above 6,300 ahead of the July 4 holiday, but just as traders reach for the champagne, a popular market indicator is <a href="https://www.benzinga.com/trading-ideas/technicals">starting to flash red.</a>
<h2 class="wp-block-heading">S&amp;P 500&#8217;s RSI Enters Overbought Territory: Why It Matters</h2>
The S&amp;P 500&#8217;s 14-day Relative Strength Index (RSI), a momentum oscillator that measures the speed and magnitude of price movements, surged to 75.62 on Wednesday, well into the overbought zone above 70.
The RSI ranges from 0 to 100, and traders use it to gauge whether an asset is overbought or oversold. While it doesn&#8217;t predict direction, history shows it often coincides with key market turning points.
In fact, in several recent cases where the S&amp;P 500's RSI hit similarly overbought levels, the index was soon met with sharp and swift pullbacks.
<ul class="wp-block-list">
<li>July 2024: RSI spiked above 75, and the index dropped 10% from 5,660 to August 6</li>
<li>July 2023: RSI flagged overbought, and the S&amp;P 500 slid 10% through late October</li>
<li>September 2020: RSI hit 83 before a rapid 10% decline that same month. </li>
<li>January 2018: RSI hit climbed to 86 after a 7% rally. The index then plunged 12% in just nine trading days during early February.</li>
</ul>
Still, the RSI is not a crystal ball.
In December 2023, the indicator was also overbought, but the S&amp;P 500 – as tracked by the Vanguard S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – kept climbing and added over 15% until April 2024.
Similarly, in December 2019, a reading of 78 did little to slow momentum until COVID-19, a rather unpredictable event, caused the market to crash two months later.
While the RSI's track record shows that overbought conditions can precede sharp pullbacks, it's not a guaranteed signal — especially in a market driven by strong momentum, AI optimism, and resilient economic data. Still, with the S&amp;P 500 at record highs and sentiment running hot, traders may want to keep one eye on the technicals as they celebrate the holiday rally.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="529" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03115457/image-45-1024x529.png" alt="" class="wp-image-972359" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03115457/image-45-1024x529.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03115457/image-45-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03115457/image-45-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03115457/image-45-1536x794.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03115457/image-45-2048x1059.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46225431/alphabet-stock-google-analysis-valuations-outlook">This Magnificent 7 Stock Is Absurdly Cheap – It Probably Won&#8217;t Stay That Way For Long </a></li>
</ul>
Photo: Shutterstock

Technicals

The S&P 500 Sank 10% The Last Time This Warning Flashed

Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2025 are expected to include acquired IPR&amp;D and milestones expense of $823 million on a pre-tax basis, representing an unfavorable impact of $0.42 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended June 30, 2025 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.

&nbsp;
While acquired IPR&amp;D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&amp;D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2025 previously announced on April&nbsp;25, 2025 excluded the impact of acquired IPR&amp;D and milestones expense that may be incurred beyond the first quarter of 2025. AbbVie&#39;s full-year 2025 adjusted diluted earnings per share guidance range, including the impact of second quarter 2025 acquired IPR&amp;D and milestones expense, is $11.67 - $11.87. AbbVie&#39;s second quarter 2025 adjusted diluted earnings per share guidance range, including the impact of second quarter 2025 acquired IPR&amp;D and milestones expense, is&nbsp;

Guidance

ABBV

AbbVie Expects $823M Acquired IPR&D And Milestones Expense In Q2 2025, Reducing Non-GAAP Diluted EPS By $0.42 To $2.84-$2.88 For Q2 2025;  FY25 Adjusted Diluted EPS Guidance Range, Including The Impact Of Q2 2025 Acquired IPR&D And Milestones Expense, Is $11.67-$11.87

General

REE Automotive Receives Nasdaq Letter Regarding Minimum Bid Price

Investors with a lot of money to spend have taken a bearish stance on DeFi Development (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DFDV, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 10 options trades for DeFi Development.
This isn't normal.
The overall sentiment of these big-money traders is split between 40% bullish and 50%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $48,000, and 9, calls, for a total amount of $415,876.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $12.5 to $25.0 for DeFi Development over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for DeFi Development's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across DeFi Development's significant trades, within a strike price range of $12.5 to $25.0, over the past month.
<h3>DeFi Development 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751562692_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DFDV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/18/26</td>
<td>$13.6</td>
<td>$10.3</td>
<td>$10.6</td>
<td>$25.00</td>
<td>$97.0K</td>
<td align="right">121</td>
<td align="right">95</td>
</tr>
<tr>
<td>DFDV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$4.3</td>
<td>$3.9</td>
<td>$4.3</td>
<td>$25.00</td>
<td>$90.3K</td>
<td align="right">962</td>
<td align="right">210</td>
</tr>
<tr>
<td>DFDV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.5</td>
<td>$7.0</td>
<td>$7.5</td>
<td>$25.00</td>
<td>$62.2K</td>
<td align="right">522</td>
<td align="right">377</td>
</tr>
<tr>
<td>DFDV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$17.5</td>
<td>$14.1</td>
<td>$15.0</td>
<td>$25.00</td>
<td>$48.0K</td>
<td align="right">19</td>
<td align="right">32</td>
</tr>
<tr>
<td>DFDV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$7.5</td>
<td>$6.9</td>
<td>$7.5</td>
<td>$25.00</td>
<td>$35.2K</td>
<td align="right">522</td>
<td align="right">157</td>
</tr>
</tbody>
</table>

<h3>About DeFi Development</h3>
DeFi Development Corp is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions as well as value-add services to multifamily and commercial property professionals.
Following our analysis of the options activities associated with DeFi Development, we pivot to a closer look at the company's own performance.
<h3>Current Position of DeFi Development</h3>
<ul>
<li>With a volume of 2,047,894, the price of DFDV is up 2.26% at $20.85. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 12 days.</li>
</ul>
<h3>Professional Analyst Ratings for DeFi Development</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $45.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $45. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest DeFi Development options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Markets

DFDV

Spotlight on DeFi Development: Analyzing the Surge in Options Activity

Whales with a lot of money to spend have taken a noticeably bearish stance on Adobe.
Looking at options history for Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) we detected 26 trades.
If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish expectations and 57% with bearish.
From the overall spotted trades, 9 are puts, for a total amount of $611,973 and 17, calls, for a total amount of $1,338,990.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $250.0 to $540.0 for Adobe over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Adobe stands at 492.36, with a total volume reaching 1,107.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Adobe, situated within the strike price corridor from $250.0 to $540.0, throughout the last 30 days.
<h3>Adobe 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751562687_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADBE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$30.7</td>
<td>$29.6</td>
<td>$30.0</td>
<td>$405.00</td>
<td>$600.0K</td>
<td>265</td>
<td align="right">1</td>
</tr>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$18.3</td>
<td>$18.05</td>
<td>$18.3</td>
<td>$370.00</td>
<td>$183.0K</td>
<td>422</td>
<td align="right">142</td>
</tr>
<tr>
<td>ADBE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$6.5</td>
<td>$5.85</td>
<td>$5.85</td>
<td>$385.00</td>
<td>$91.2K</td>
<td>464</td>
<td align="right">8</td>
</tr>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/20/26</td>
<td>$28.4</td>
<td>$26.8</td>
<td>$27.71</td>
<td>$360.00</td>
<td>$83.1K</td>
<td>1.1K</td>
<td align="right">30</td>
</tr>
<tr>
<td>ADBE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$26.0</td>
<td>$25.05</td>
<td>$25.2</td>
<td>$380.00</td>
<td>$70.4K</td>
<td>767</td>
<td align="right">36</td>
</tr>
</tbody>
</table>

<h3>About Adobe</h3>
Adobe provides content creation, document management, and digital marketing and advertising software and services to creative professionals and marketers for creating, managing, delivering, measuring, optimizing, and engaging with compelling content multiple operating systems, devices, and media. The company operates with three segments: digital media content creation, digital experience for marketing solutions, and publishing for legacy products (less than 5% of revenue).
In light of the recent options history for Adobe, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Adobe</h3>
<ul>
<li>Trading volume stands at 2,021,019, with ADBE's price up by 0.62%, positioned at $380.83.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 70 days.</li>
</ul>
<h3>What Analysts Are Saying About Adobe</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $471.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Mizuho has decided to maintain their Outperform rating on Adobe, which currently sits at a price target of $530. 
&#x2A; An analyst from Evercore ISI Group downgraded its action to Outperform with a price target of $475. 
&#x2A; In a cautious move, an analyst from BMO Capital downgraded its rating to Outperform, setting a price target of $450. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Adobe, which currently sits at a price target of $475. 
&#x2A; Consistent in their evaluation, an analyst from Baird keeps a Neutral rating on Adobe with a target price of $425. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Adobe, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

ADBE

Adobe Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Oklo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with OKLO, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 18 uncommon options trades for Oklo.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 16%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $357,612, and 12 are calls, for a total amount of $525,352.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $60.0 for Oklo over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Oklo's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Oklo's substantial trades, within a strike price spectrum from $40.0 to $60.0 over the preceding 30 days.
<h3>Oklo Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751562681_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>OKLO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/03/25</td>
<td>$3.3</td>
<td>$2.51</td>
<td>$2.97</td>
<td>$55.00</td>
<td>$133.6K</td>
<td>1.8K</td>
<td align="right">458</td>
</tr>
<tr>
<td>OKLO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$9.4</td>
<td>$9.1</td>
<td>$9.24</td>
<td>$60.00</td>
<td>$95.1K</td>
<td>1.0K</td>
<td align="right">104</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$16.2</td>
<td>$14.9</td>
<td>$15.18</td>
<td>$41.00</td>
<td>$80.8K</td>
<td>260</td>
<td align="right">50</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$15.9</td>
<td>$15.35</td>
<td>$15.95</td>
<td>$40.00</td>
<td>$79.7K</td>
<td>1.1K</td>
<td align="right">62</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$4.95</td>
<td>$4.9</td>
<td>$4.95</td>
<td>$60.00</td>
<td>$49.5K</td>
<td>1.8K</td>
<td align="right">838</td>
</tr>
</tbody>
</table>

<h3>About Oklo</h3>
Oklo Inc is developing advanced fission power plants to provide clean, reliable, and affordable energy at scale. It is pursuing two complementary tracks to address this demand: providing reliable, commercial-scale energy to customers; and selling used nuclear fuel recycling services to the U.S. market. The Company plans to commercialize its liquid metal fast reactor technology with the Aurora powerhouse product line. The first commercial Aurora powerhouse is designed to produce up to 15 megawatts of electricity (MWe) on both recycled nuclear fuel and fresh fuel.
Following our analysis of the options activities associated with Oklo, we pivot to a closer look at the company's own performance.
<h3>Current Position of Oklo</h3>
<ul>
<li>Trading volume stands at 7,745,076, with OKLO's price up by 3.23%, positioned at $52.99.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 40 days.</li>
</ul>
<h3>Professional Analyst Ratings for Oklo</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $73.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Seaport Global has elevated its stance to Buy, setting a new price target at $71. 
&#x2A; An analyst from Wedbush persists with their Outperform rating on Oklo, maintaining a target price of $75. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Oklo with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

OKLO

This Is What Whales Are Betting On Oklo

WIIM

SY stock has given up its prior gain. So-Young International shares were trading higher after the company regained Nasdaq compliance for its closing bid price.

Offerings

QUBT

Quantum Computing Files For Resale Of Up To 14.04M Shares Of Common Stock By The Selling Stockholder

Goldman Sachs analyst Mark Delaney maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Neutral and raises the price target from $285 to $315.

Goldman Sachs Maintains Neutral on Tesla, Raises Price Target to $315

<a href="https://www.bloomberg.com/news/articles/2025-07-03/china-set-to-cancel-part-of-eu-summit-in-latest-strain-on-ties?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-07-03/china-set-to-cancel-part-of-eu-summit-in-latest-strain-on-ties?embedded-checkout=true</a>

'China Set to Cancel Part of EU Summit in Latest Strain on Ties'- Bloomberg

<h3>Gainers</h3>
<ul>
<li>Xponential Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPOF#NYSE">XPOF</a>) shares moved upwards by 35.2% to $10.09 during Thursday's regular session. The market value of their outstanding shares is at $260.5 million. </li>
<li>707 Cayman Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JEM#NASDAQ">JEM</a>) stock rose 30.42% to $5.08. The company's market cap stands at $85.4 million. </li>
<li>Fenbo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEBO#NASDAQ">FEBO</a>) shares rose 17.5% to $1.1. The market value of their outstanding shares is at $10.3 million. </li>
<li>Alliance Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AENT#NASDAQ">AENT</a>) shares moved upwards by 15.78% to $5.28. The company's market cap stands at $232.3 million. </li>
<li>Faraday Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) shares increased by 15.33% to $1.88. The market value of their outstanding shares is at $160.6 million. </li>
<li>Noodles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDLS#NASDAQ">NDLS</a>) stock rose 13.95% to $0.81. The company's market cap stands at $32.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Xcel Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELB#NASDAQ">XELB</a>) shares fell 19.4% to $1.53 during Thursday's regular session. The market value of their outstanding shares is at $4.5 million. </li>
<li>BT Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBD#NASDAQ">BTBD</a>) shares fell 17.53% to $1.13. The company's market cap stands at $8.4 million. </li>
<li>Mullen Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) stock declined by 17.34% to $0.23. </li>
<li>GreenTree Hospitality Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHG#NYSE">GHG</a>) stock declined by 11.05% to $2.17. The market value of their outstanding shares is at $247.7 million. </li>
<li>U Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCAR#NASDAQ">UCAR</a>) stock decreased by 10.43% to $4.04. The company's market cap stands at $19.9 million. </li>
<li>Epsium Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPSM#NASDAQ">EPSM</a>) stock declined by 10.22% to $14.19. The company's market cap stands at $212.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AENT

BTBD

EPSM

FEBO

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

MULN

NDLS

UCAR

XELB

XPOF

12 Consumer Discretionary Stocks Moving In Thursday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock moved upwards by 120.3% to $22.82 during Thursday's regular session. The market value of their outstanding shares is at $5.1 billion. As per the news, the H1 earnings report came out 3 days ago. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) shares increased by 41.48% to $2.86. The market value of their outstanding shares is at $5.5 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) stock moved upwards by 31.37% to $1.91. The market value of their outstanding shares is at $181.1 million. </li>
<li>Jupiter Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) shares rose 31.14% to $1.56. The company's market cap stands at $39.3 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) stock rose 27.97% to $2.47. The market value of their outstanding shares is at $14.3 million. </li>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) stock moved upwards by 23.53% to $0.41. The market value of their outstanding shares is at $20.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares declined by 37.9% to $1.33 during Thursday's regular session. The company's market cap stands at $78.4 million. </li>
<li>Jyong Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MENS#NASDAQ">MENS</a>) shares decreased by 17.68% to $7.92. The company's market cap stands at $731.3 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares decreased by 11.74% to $0.56. The company's market cap stands at $28.4 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) stock fell 11.34% to $2.75. The company's market cap stands at $9.7 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock fell 10.54% to $2.64. The market value of their outstanding shares is at $5.4 million. </li>
<li>Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) shares declined by 10.41% to $2.41. The company's market cap stands at $81.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CGTX

GTBP

JUNS

LIXT

MENS

ONMD

VERO

ZYXI

12 Health Care Stocks Moving In Thursday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>HUHUTECH International Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUHU#NASDAQ">HUHU</a>) stock rose 23.8% to $7.5 during Thursday's regular session. The market value of their outstanding shares is at $128.3 million. </li>
<li>Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) stock moved upwards by 23.42% to $4.11. The company's market cap stands at $114.5 million. </li>
<li>NET Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPWR#NYSE">NPWR</a>) stock rose 22.83% to $3.12. The company's market cap stands at $197.4 million. </li>
<li>Concorde Intl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIGL#NASDAQ">CIGL</a>) stock rose 19.04% to $22.19. The company's market cap stands at $416.1 million. </li>
<li>Galaxy Payroll Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXG#NASDAQ">GLXG</a>) stock rose 18.16% to $0.65. The company's market cap stands at $9.9 million. </li>
<li>Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) shares increased by 17.18% to $10.54. The company's market cap stands at $2.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Air T (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRT#NASDAQ">AIRT</a>) stock decreased by 20.0% to $16.9 during Thursday's regular session. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>Nuburu (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BURU#AMEX">BURU</a>) stock declined by 9.47% to $0.36. The market value of their outstanding shares is at $24.8 million. </li>
<li>Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) shares fell 9.31% to $21.92. The market value of their outstanding shares is at $313.9 million. The company's, Q3 earnings came out yesterday. </li>
<li>EuroDry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDRY#NASDAQ">EDRY</a>) shares declined by 9.24% to $8.84. The company's market cap stands at $27.5 million. </li>
<li>Clean Energy Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETY#NASDAQ">CETY</a>) stock fell 8.15% to $0.21. The company's market cap stands at $14.5 million. </li>
<li>Pinnacle Food Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFAI#NASDAQ">PFAI</a>) stock declined by 7.82% to $1.65. The company's market cap stands at $20.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRT

BURU

CETY

CIGL

EDRY

GLXG

HUHU

NPWR

PFAI

SRFM

12 Industrials Stocks Moving In Thursday's Intraday Session

Health Care

Press Releases

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Virtual Investor Releases Next Wave of "Top 5 for '25" On-Demand Videos

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Management

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Sonnet Announces Release of Corporate Update Video

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Sonnet Releases Virtual Investor "What This Means" Segment

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

Comments

Sonnet BioTherapeutics

Intérêt court

Sonnet BioTherapeutics (NASDAQ:SONN) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL